| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-91245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-90245 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-366
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-366
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
| filingDate |
2002-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2008-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53e4643bc2dbfefcbc6462322c714f03 |
| publicationDate |
2008-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7407772-B2 |
| titleOfInvention |
Screening and selection methods for statin drug combinations |
| abstract |
A method for screening statins in their open acid form to determine the susceptibility of each tested statin to metabolic glucuronidation is provided. Also provided is a method for determining if a non-statin pharmaceutical drug co-administered with a statin that is susceptible to metabolic glucuronidation in its open acid form, will inhibit the glucuronidation of the statin and thereby increase the risk of an adverse drug interaction. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012107814-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9528156-B2 |
| priorityDate |
2001-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |